Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

  • STATUS
    Recruiting
  • End date
    Jun 28, 2022
  • participants needed
    36
  • sponsor
    M.D. Anderson Cancer Center
Updated on 28 July 2021
cancer
fludarabine
cyclophosphamide
tyrosine
lymphoma
leukemia
gilbert's syndrome
oximetry
chemotherapy drug
chemotherapy drugs
b-cell lymphoma
chemoimmunotherapy

Summary

If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant.

The goal of this clinical research study is to learn if giving genetically changed immune cells, called CAR-NK cells, after chemotherapy will improve the disease in stem cell transplant patients with relapsed (has returned) and/or refractory (has not responded to treatment) B-cell lymphoma or leukemia. Also, researchers want to find the highest tolerable dose of CAR-NK cells to give to patients with relapsed or refractory B-cell lymphoma or leukemia. The safety of this treatment will also be studied.

This is an investigational study. The making of and infusion of genetically changed NK cells and the drug AP1903 (if you receive it, explained below) are not FDA approved or commercially available for use in this type of disease. They are currently being used for research purposes only. The chemotherapy drugs in this study (fludarabine, cyclophosphamide, and mesna) are commercially available and FDA approved.

Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.

Description

Objectives

Primary objective:

To determine the safety and relative efficacy of Chimeric antigen receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer (CB-NK) cells in patients with relapsed/refractory CD19+ B lymphoid malignancies.

Secondary Objectives:

  1. To assess the overall response rate (complete and partial response rates).
  2. To quantify persistence of infused allogeneic donor CAR-transduced CB-derived NK cells in the recipient.
  3. To conduct comprehensive immune reconstitution studies.

Details
Condition childhood ALL, Lymphoma, Lymphoma, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Chronic, Non-Hodgkin's Lymphoma, Lymphocytic Leukemia, Acute, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies, leukemia, acute lymphoblastic, non-hodgkin's lymphoma (nhl), leukemia chronic lymphocytic, chronic lymphocytic leukemia (cll), small lymphocytic lymphoma, acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all), B-Lymphoid Malignancies, B-Lymphoid Malignancies, B-Lymphoid Malignancies
Treatment cyclophosphamide, Fludarabine, MESNA, AP1903, iC9/CAR.19/IL15-Transduced CB-NK Cells
Clinical Study IdentifierNCT03056339
SponsorM.D. Anderson Cancer Center
Last Modified on28 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with history of CD 19 positive B-lymphoid malignancies (ALL, CLL, NHL) who have received at least 2 lines of standard chemoimmunotherapy or targeted therapy and have persistent disease
Patients with ALL, CLL, NHL with relapsed disease following standard therapy or a stem cell transplant
Patients at least 3 weeks from last cytotoxic chemotherapy at the time of starting lymphodepleting chemotherapy. Patients may continue tyrosine kinase inhibitors or other targeted therapies until at least two weeks prior to administration of lymphodepleting chemotherapy
Karnofsky/Lansky Performance Scale > 70\
Adequate organ function: a. Renal: Creatinine clearance (as estimated by Cockcroft Gault) >/= 60 cc/min. b. Hepatic: ALT/AST </= 2.5 x ULN or </= 5 x ULN if documented liver metastases, Total bilirubin </= 1.5 mg/dL, except in subjects with Gilbert's Syndrome in whom total bilirubin must be </= 3.0 mg/dL. c. Cardiac: Cardiac ejection fraction >/= 50%, no evidence of pericardial effusion as determined by an ECHO or MUGA, and no clinically significant ECG findings. d. Pulmonary: No clinically significant pleural effusion, baseline oxygen saturation > 92% on room air
Able to provide written informed consent
7-80 years of age
All participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor
Signed consent to long-term follow-up protocol PA17-0483

Exclusion Criteria

Positive beta HCG in female of child-bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females
Known positive serology for HIV
Presence of Grade 3 or greater toxicity from the previous treatment
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management. Note: Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
Presence of active neurological disorder(s)
Concomitant use of other investigational agents
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note